Carregant...

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology

BACKGROUND: Incremental cost-effectiveness ratios (ICERs) are used to assess the value for money of new drugs. Many believe that ICERs for drugs that treat rare diseases are much higher than those of common drugs. Our objective was to compare the proportion of ICERs that are cost effective for rare...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoecon Open
Autors principals: Jayasundara, Kavisha, Krahn, Murray, Mamdani, Muhammad, Hoch, Jeffrey S., Grootendorst, Paul
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691840/
https://ncbi.nlm.nih.gov/pubmed/29441496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-017-0022-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!